Ivax Glucovance generic approved
Executive Summary
FDA approves Ivax' ANDA for generic version of Bristol-Myers Squibb's Glucovance (glyburide/metformin) with 180 days of marketing exclusivity Feb. 18. Ivax says it is building inventory for launch. Glucovance lost marketing exclusivity Jan. 31. Ivax is in the middle of 180-day exclusivity for metformin extended-release (Bristol's Glucophage XR) (1"The Pink Sheet" Dec. 1, 2003, p. 17)...
You may also be interested in...
Glucovance generics launch
Ivax launches its generic version of Bristol-Myers Squibb's Glucovance (glyburide/ metformin) May 4, triggering 180 days of marketing exclusivity. Par entered the market with an "authorized" generic the same day. Ivax has been building inventory since ANDA approval Feb. 18 (1"The Pink Sheet" Feb. 23, 2004, In Brief)...
Glucophage XR Settlement: Purepac, Ivax Split Generic Profits For 180 Days
Ivax and Purepac's exclusivity rights settlement for a generic version of Glucophage XR means FDA has avoided a legal challenge to its interpretation of first-to-file requirements for new ANDAs compared to amended applications
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”